Status:
ACTIVE_NOT_RECRUITING
Pneumococcal Conjugated Vaccine 13 (PCV13) for Patients With Multiple Myeloma (MM)
Lead Sponsor:
National Taiwan University Hospital
Collaborating Sponsors:
Ministry of Health and Welfare, Taiwan
Conditions:
Multiple Myeloma
Eligibility:
All Genders
20+ years
Phase:
PHASE4
Brief Summary
Multiple myeloma patients often get serious infections that can be deadly. A British study looked at newly diagnosed patients and found that bacterial infections were the main cause of death in the fi...
Detailed Description
Infection has always been a common and potentially life-threatening problem for multiple myeloma patients. A British study on newly diagnosed multiple myeloma patients investigated the causes of death...
Eligibility Criteria
Inclusion
- Patients with multiple myeloma
- Stable clinical condition to have vaccination at outpatient clinic
Exclusion
- Those who have received pneumococcal vaccine within the past five years
- Unable to communicate verbally with the subject
- Subject has an active infection
- Pregnant women
Key Trial Info
Start Date :
March 23 2016
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 31 2027
Estimated Enrollment :
101 Patients enrolled
Trial Details
Trial ID
NCT07154537
Start Date
March 23 2016
End Date
July 31 2027
Last Update
September 4 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Taiwan University Hospital
Taipei, Taipei, Taiwan, 100226